5'-Guanidino Xylofuranosyl Nucleosides as Novel Types of 5'-Functionalized Nucleosides with Therapeutic Potential

31 January 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The synthesis and biological evaluation of 5′-guanidino furanosyl nucleosides comprising 6-chloropurine and uracil moieties and a 3-O-benzyl xylofuranosyl unit is presented. Their access was based on the N-glycosylation of a 5-azido 3-O-benzyl xylofuranosyl acetate donor with the silylated nucleobase and a subsequent one-pot sequential two-step protocol involving Staudinger reduction of the thus obtained 5-azido uracil and N7/N9-linked purine nucleosides followed by guanidinylation with N,N’-bis(tert-butoxycarbonyl)-N’’-triflylguanidine. Bioactivity screening revealed the significant activities exhibited among the synthesized compounds, namely abilities to inhibit butyrylcholinesterase (BChE), a therapeutic target for the symptomatic treatment of latter stages of Alzheimer’s disease, cytotoxic activities against cancer cells, and/or neuroprotective effects. 5′-Guanidino 6-chloropurine nucleosides were shown to act as mixed-type and selective submicromolar or micromolar BChE inhibitors, from which the N9 nucleoside was the most prominent compound with inhibition constants Ki / Ki' of 0.89 μM / 2.96 μM, besides showing low cytotoxicity to FL83B hepatocytes and no significant cytotoxicity to human neuroblastoma cells (SH-SY5Y). Moreover, the N9-linked nucleoside exhibited selective cytotoxic activity to prostate cancer cells (DU-145, IC50 = 27.63 μM), while its N7 regioisomer was active against all cancer cells tested [DU-145, IC50 = 24.48 μM; colorectal adenocarcinoma (HCT-15, IC50 = 64.07 μM); and breast adenocarcinoma (MCF-7, IC50 = 43.67 μM)]. In turn, the 5'-guanidino uracil nucleoside displayed selective cytotoxicity to HCT-15 cells (IC50 = 76.02 μM) and showed also neuroprotective potential in a Parkinson’s disease SH-SY5Y cells’ damage model. The active molecules exhibited IC50 values to the affected cancer cells close or lower than those of standard drugs, and comparable or not significant neuro- and hepatotoxicity.

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.